arthritis advocacy news and regulatory letters

Advocacy News & Regulatory Letters

February 17, 2017

Arthritis Foundation Submits Comments to The Institute for Clinical and Economic Review (ICER) on their Draft Evidence Report for their Review of Rheumatoid Arthritis Drugs

The Institute for Clinical and Economic Review (ICER) recently published a draft evidence report on the review of rheumatoid arthritis (RA) drugs. The Arthritis Foundation has provided written and verbal commentary to ICER on this report to help to ensure that patient voices are heard by ICER. It is imperative that input from patients and providers is considered and included during the development of a review for life changing treatments like those used for rheumatoid arthritis. Read the letter here.

Visit our page to learn more about the written and verbal commentary we have provided to ICER.

February 13, 2017

Arthritis Foundation Signs Letter to the Trump Administration in Support of Patient Centered Health Care Reform

The Arthritis Foundation, along with 200 other patient and community organizations, signed onto an I Am Essential coalition letter to the newly confirmed Secretary of Health and Human Services, Tom Price. The letter advocates for patient centric health reform legislation and urges the Trump administration to maintain the many important protections patients have gained through the Affordable Care Act that ensure they can access the care and treatment their providers prescribe. In the letter, the coalition supports accessibility, affordability, quality, responsiveness, choices and transparency, and innovative patient-care. Read the letter here.

January 30, 2017

Arthritis Foundation Provides Written and Verbal Commentary to Institute for Clinical and Economic Review (ICER)

ICER is a Boston-based non-profit organization that evaluates the clinical effectiveness and the cost of medical tests, treatments and delivery system innovations. Currently, ICER is reviewing rheumatoid arthritis therapies and will develop a report assessing their clinical effectiveness and value. ICER has also developed a value assessment framework to assess the cost and value of medications that many stakeholders have called into question. The Arthritis Foundation has provided written and verbal commentary and input to ICER at all available points so far in this evaluation process for RA drugs.

Visit our page to learn more about the written and verbal commentary we have provided and to see the summary of the remaining timeline in ICER’s review process for RA drugs.

Older News by Year